PUBLISHER: Grand View Research | PRODUCT CODE: 1404817
PUBLISHER: Grand View Research | PRODUCT CODE: 1404817
The global hospital acquired infections diagnostics market is expected to reach USD 7.15 billion by 2030, according to a new report by Grand View Research, Inc. The global hospital acquired infections diagnostics market is projected to grow at a healthy CAGR of 7.2% during the period of 2023 to 2030. Factors attributing to the growth of the market are increase in the number of drug-resistant pathogens such as MRSA and C. difficile, advancing age of geriatric population, and development of technologically advanced products that offer accurate and reliable results with low turnaround time.
Another factor contributing to industry growth is the increasing demand of HAI diagnostics from middle and low income countries, further driving demand for HAI diagnostic market. Increasing awareness among healthcare workers and proposed government initiatives are further supporting industry growth. However, decline in the prevalence rate of nosocomial infections in the developed countries is likely to hinder industry growth.
The HAI diagnostics market is categorized on the basis of infection type and test type. On the basis of infection type, the market is segmented into Urinary Tract Infection (UTI), Blood Stream Infection (BSI), Surgical Site Infection (SSI), pneumonia, and others. As of 2015, the urinary tract infection segment was estimated to account for the largest share, whereas the pneumonia HAI diagnostics is projected to grow at the highest CAGR during the period of 2015 to 2022.The HAI diagnostics industry is further segmented into molecular tests and other in-vitro tests. Though the molecular diagnostics segment is estimated to constitute a low share, it is anticipated to witness a lucrative growth in the next few years.